Please ensure Javascript is enabled for purposes of website accessibility

Bristol Myers Squibb's Latest Data Could Help the Pharma Leapfrog Rival Merck

By Brian Orelli, PhD and Keith Speights - May 3, 2021 at 7:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

LAG-3 is the new PD-1.

In this video from Motley Fool Live, recorded on March 29, contributors Brian Orelli and Keith Speights discuss how Bristol Myers Squibb (BMY -0.21%) can maximize the value of its LAG-3 inhibitor, relatlimab, now that the pharmaceutical company has shown it works with its PD-1 drug, Opdivo. On the flip side, the loser here could be Merck (MRK 1.37%), which has a PD-1 drug, Keytruda, but is currently lagging Bristol Myers Squibb in the LAG-3 arena.

Brian Orelli: I counted seven different programs in phase 2 for drugs that are targeting LAG-3: Incyte; Merck; Regeneron; Novartis, which is working with Immutep; and I think Immutep has one on their own; and there are some others.

Merck really stood out there since it has Keytruda, which competes with Opdivo. They're obviously combining [Bristol Myers Squibb's] LAG-3 with Opdivo. But Keytruda has really been taking market share, I think, from Opdivo in the PD-1 space. This really seems like the data that shows that Bristol's LAG-3 and Opdivo works well in melanoma, might give it a fighting chance to look at other indications before Merck has a chance to catch up.

Keith Speights: Yeah. I would agree. Merck and Bristol Myers Squibb are the top two players in PD-1 right now. But Keytruda, like you said, has emerged as the bigger winner in the head-to-head battle against Opdivo. But the next frontier for immunotherapies, I think, are in combination therapies, and we've already seen several combos win approval already, more likely on the way. But Bristol's lead in anti-LAG-3 could give it a pretty significant competitive advantage in the near future, and I think it's one that the company could really use. I think this could end up helping boost Opdivo's market position against Keytruda, if we see combo therapies come out.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$76.84 (-0.21%) $0.16
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$92.42 (1.37%) $1.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.